A study newly published in the Journal of Clinical Oncology found that SB3, a proposed trastuzumab biosimilar being developed by Samsung Bioepis, demonstrated equivalence with European-sourced reference trastuzumab (Herceptin) in terms of breast pathologic complete response (bpCR) rate. Safety and immunogenicity for the 2 drugs were also similar.
A study newly published in the Journal of Clinical Oncology found that SB3, a proposed trastuzumab biosimilar being developed by Samsung Bioepis, demonstrated equivalence with European-sourced reference trastuzumab (Herceptin) in terms of breast pathologic complete response (bpCR) rate. Safety and immunogenicity for the 2 drugs were also similar.
The phase 3, randomized, double-blind, parallel-group, multicenter study, led by Xavier Pivot, MD, PhD, included patients aged 18 to 65 who had HER2-positive breast cancer. A total of 875 patients, the full analysis set (FAS), were randomized to receive either SB3 (n = 437) or the European-sourced reference Herceptin (n = 438). In total, 800 patients, the per protocol set (PPS) completed 8 cycles of neoadjuvant therapy and surgery (SB3, n = 402; reference, n = 398).
The primary endpoint of the study was the bpCR rate, defined as no histologic evidence of residual invasive tumor cells in the breast. Equivalence in terms of bpCR was declared if the 95% confidence interval (CI) of the ratio was within 0.785 to 1.546, or the 95% CI of the difference was within plus or minus 13%.
To assess safety, treatment-emergent adverse events (TEAEs) were assessed throughout the study. Blood samples were collected to assess pharmacokinetics (PK), and immunogenicity testing was performed to search for anti-drug antibodies (ADAs). At the time of data cutoff, the median follow-up durations were 337 days (range, 94 to 485 days) and 338 days (range, 24 to 475 days) in the SB3 and reference arms, respectively.
The researchers found the following with respect to efficacy:
In terms of safety, the researchers report the following:
With respect to PK, the researchers report that, in the PK population of 161 and 152 patients in the SB3 and reference arms, respectively, mean Ctrough profiles from cycle 3 to cycle 8 were similar. In terms of immunogenicity, up to cycle 9, 3 patients in the SB3 group were positive for ADAs. No patients in the reference group were ADA-positive for the same period.
The authors concluded that their data demonstrate the similarity of SB3 and the reference Herceptin. Patients may continue in a long-term extension of the study that will further monitor safety, event-free survival, and overall survival.
The FDA is currently reviewing Samsung Bioepis’ Biologics License Application for SB3, which has already been approved for marketing by the European Commission and the Republic of Korea.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.
New Year, New Hurdles: What's in Store for Biosimilars in 2023
December 18th 2022On this episode, Brian Biehn, senior director of biosimilar commercialization at AmerisourceBergen, explored how the new year may play out for biosimilars, including his predictions or how uptake will be influenced in the adalimumab market and how government policies will impact the competitiveness of the market.
Part 1: Oncology Biosimilars Offer Comparable Benefits to Originators at Lower Prices
November 14th 2023In part 1 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® looks at a retrospective study comparing the clinical benefits, price changes, and uptake associated with oncology biosimilars in China.
Eye on Pharma: Denosumab Biosimilar Data; COA Forms New Committee; IGBA and WHO Collaborate
November 8th 2023Samsung Bioepis releases data for its denosumab biosimilar candidate; the Community Oncology Alliance (COA) forms the Drug Policy and Regulation Committee; the International Generic and Biosimilar Association (IGBA) and the World Health Organization (WHO) collaborate on a new initiative.